These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23333901)

  • 1. Administration of the optimized β-Lapachone-poloxamer-cyclodextrin ternary system induces apoptosis, DNA damage and reduces tumor growth in a human breast adenocarcinoma xenograft mouse model.
    Seoane S; Díaz-Rodríguez P; Sendon-Lago J; Gallego R; Pérez-Fernández R; Landin M
    Eur J Pharm Biopharm; 2013 Aug; 84(3):497-504. PubMed ID: 23333901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy.
    Dong Y; Chin SF; Blanco E; Bey EA; Kabbani W; Xie XJ; Bornmann WG; Boothman DA; Gao J
    Clin Cancer Res; 2009 Jan; 15(1):131-9. PubMed ID: 19118040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.
    Ma X; Huang X; Moore Z; Huang G; Kilgore JA; Wang Y; Hammer S; Williams NS; Boothman DA; Gao J
    J Control Release; 2015 Feb; 200():201-11. PubMed ID: 25542645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells.
    Blanco E; Bey EA; Dong Y; Weinberg BD; Sutton DM; Boothman DA; Gao J
    J Control Release; 2007 Oct; 122(3):365-74. PubMed ID: 17574288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Lapachone promotes the recruitment and polarization of tumor-associated neutrophils (TANs) toward an antitumor (N1) phenotype in NQO1-positive cancers.
    Tumbath S; Jiang L; Li X; Zhang T; Zahid KR; Zhao Y; Zhou H; Yin Z; Lu T; Jiang S; Chen Y; Chen X; Fu YX; Huang X
    Oncoimmunology; 2024; 13(1):2363000. PubMed ID: 38846085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
    Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
    Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of NAD(P)H:quinone oxidoreductase by radiation potentiates the effect of bioreductive beta-lapachone on cancer cells.
    Choi EK; Terai K; Ji IM; Kook YH; Park KH; Oh ET; Griffin RJ; Lim BU; Kim JS; Lee DS; Boothman DA; Loren M; Song CW; Park HJ
    Neoplasia; 2007 Aug; 9(8):634-42. PubMed ID: 17786182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.
    Wu Y; Wang X; Chang S; Lu W; Liu M; Pang X
    J Pharmacol Exp Ther; 2016 Jun; 357(3):466-75. PubMed ID: 27048660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic delivery and preclinical evaluation of Au nanoparticle containing beta-lapachone for radiosensitization.
    Jeong SY; Park SJ; Yoon SM; Jung J; Woo HN; Yi SL; Song SY; Park HJ; Kim C; Lee JS; Lee JS; Choi EK
    J Control Release; 2009 Nov; 139(3):239-45. PubMed ID: 19619590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
    Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
    Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
    Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
    Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.
    Ma X; Moore ZR; Huang G; Huang X; Boothman DA; Gao J
    J Drug Target; 2015; 23(7-8):672-80. PubMed ID: 26453163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-cancer effect of bio-reductive drug beta-lapachon is enhanced by activating NQO1 with heat shock.
    Song CW; Chae JJ; Choi EK; Hwang TS; Kim C; Lim BU; Park HJ
    Int J Hyperthermia; 2008 Mar; 24(2):161-9. PubMed ID: 18283592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of various formulation approaches for the application of beta-lapachone in prostate cancer therapy.
    Wu X; Kasselouri A; Vergnaud-Gauduchon J; Rosilio V
    Int J Pharm; 2020 Apr; 579():119168. PubMed ID: 32087264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-lapachone: A Promising Anticancer Agent with a Unique NQO1 Specific Apoptosis in Pancreatic Cancer.
    Qadir MI; Iqbal MS; Khan R
    Curr Cancer Drug Targets; 2022; 22(7):537-540. PubMed ID: 35490325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
    Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
    Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.
    Kung HN; Weng TY; Liu YL; Lu KS; Chau YP
    PLoS One; 2014; 9(2):e88122. PubMed ID: 24505400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation.
    Wang F; Blanco E; Ai H; Boothman DA; Gao J
    J Pharm Sci; 2006 Oct; 95(10):2309-19. PubMed ID: 16883563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel β-carboline-based indole-4,7-quinone derivatives as NAD(P)H: Quinone-oxidoreductase-1 inhibitor with potent antitumor activities by inducing reactive oxygen species, apoptosis, and DNA damage.
    Guo Y; Xu L; Ling C; Yang T; Zheng W; Lv J; Guo Q; Chen B
    Chem Biol Drug Des; 2020 Dec; 96(6):1433-1446. PubMed ID: 32592323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
    Dong Y; Bey EA; Li LS; Kabbani W; Yan J; Xie XJ; Hsieh JT; Gao J; Boothman DA
    Cancer Res; 2010 Oct; 70(20):8088-96. PubMed ID: 20940411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.